JP6921755B2 - 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 - Google Patents

脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 Download PDF

Info

Publication number
JP6921755B2
JP6921755B2 JP2017549860A JP2017549860A JP6921755B2 JP 6921755 B2 JP6921755 B2 JP 6921755B2 JP 2017549860 A JP2017549860 A JP 2017549860A JP 2017549860 A JP2017549860 A JP 2017549860A JP 6921755 B2 JP6921755 B2 JP 6921755B2
Authority
JP
Japan
Prior art keywords
wnt5a
cells
tumor
cell
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549860A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500390A5 (cg-RX-API-DMAC7.html
JP2018500390A (ja
Inventor
アンジェロ ルイージ ヴェスコヴィ
アンジェロ ルイージ ヴェスコヴィ
エレナ ビンダ
エレナ ビンダ
Original Assignee
ハイパーステム ソシエテ アノニム
ハイパーステム ソシエテ アノニム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハイパーステム ソシエテ アノニム, ハイパーステム ソシエテ アノニム filed Critical ハイパーステム ソシエテ アノニム
Publication of JP2018500390A publication Critical patent/JP2018500390A/ja
Publication of JP2018500390A5 publication Critical patent/JP2018500390A5/ja
Application granted granted Critical
Publication of JP6921755B2 publication Critical patent/JP6921755B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2017549860A 2014-12-10 2015-12-09 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物 Active JP6921755B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462090029P 2014-12-10 2014-12-10
US62/090,029 2014-12-10
PCT/IB2015/002577 WO2016092378A1 (en) 2014-12-10 2015-12-09 Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors

Publications (3)

Publication Number Publication Date
JP2018500390A JP2018500390A (ja) 2018-01-11
JP2018500390A5 JP2018500390A5 (cg-RX-API-DMAC7.html) 2019-01-24
JP6921755B2 true JP6921755B2 (ja) 2021-08-18

Family

ID=55353245

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549860A Active JP6921755B2 (ja) 2014-12-10 2015-12-09 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物

Country Status (9)

Country Link
US (2) US10688167B2 (cg-RX-API-DMAC7.html)
EP (1) EP3229831B1 (cg-RX-API-DMAC7.html)
JP (1) JP6921755B2 (cg-RX-API-DMAC7.html)
KR (1) KR102674191B1 (cg-RX-API-DMAC7.html)
AU (1) AU2015359043C1 (cg-RX-API-DMAC7.html)
CA (1) CA2970140A1 (cg-RX-API-DMAC7.html)
DK (1) DK3229831T3 (cg-RX-API-DMAC7.html)
ES (1) ES2796973T3 (cg-RX-API-DMAC7.html)
WO (1) WO2016092378A1 (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10852069B2 (en) 2010-05-04 2020-12-01 Fractal Heatsink Technologies, LLC System and method for maintaining efficiency of a fractal heat sink
KR102674191B1 (ko) * 2014-12-10 2024-06-11 하이퍼스템 에스에이 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물
US20210008149A1 (en) * 2017-10-25 2021-01-14 Wntresearch Ab Wnt5a peptides in reduction of cancer stem cells
KR101921836B1 (ko) 2017-11-23 2018-11-26 서울대학교병원 피부성체 줄기세포의 분화 조절 방법, 및 피부성체 줄기세포의 분화 조절용 조성물 및 키트
US20210041443A1 (en) * 2018-04-24 2021-02-11 Universidade Do Minho Wnt6 as glioblastoma oncogenic biomarker, and uses of inhibitors thereof
EP3613757A1 (en) 2018-08-20 2020-02-26 Wntresearch AB Solution phase routes for wnt hexapeptides
EP3666789A1 (en) * 2018-12-14 2020-06-17 Wntresearch AB Linear solution phase routes for wnt hexapeptides
BR112021020635A2 (pt) * 2019-04-16 2022-02-22 Wntresearch Ab Peptídeo wnt5a ou derivados do mesmo em combinação com um ou mais inibidores de ponto de controle para uso no tratamento do câncer de cólon, câncer colorretal ou câncer de mama
WO2021034784A1 (en) 2019-08-16 2021-02-25 Poltorak Technologies, LLC Device and method for medical diagnostics
CN114081954B (zh) * 2021-10-30 2023-02-28 中国人民解放军陆军军医大学第一附属医院 用于胶质母细胞瘤治疗的药物组合物以及预后的诊断试剂
WO2025088835A1 (ja) * 2023-10-25 2025-05-01 国立大学法人大阪大学 ヒト化抗ｃｋａｐ４抗体又はその抗原結合性断片

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
US4227522A (en) 1978-09-05 1980-10-14 Syntex Puerto Rico, Inc. Inhalation device
FR2550452B1 (fr) 1982-10-08 1992-05-22 Glaxo Group Ltd Dispositif pour administrer des medicaments a des patients
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
FI88112C (fi) 1985-07-30 1993-04-13 Glaxo Group Ltd Anordning foer administrering av laekemedel till patienter
JPH05963A (ja) 1990-04-13 1993-01-08 Toray Ind Inc ポリペプチド類組成物
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
EP1226172A1 (en) * 1999-11-05 2002-07-31 Forskarpatent i Syd AB Compounds, antibodies and methods for treating, preventing or diagnosing tumour metastasis
WO2006130082A1 (en) 2005-05-30 2006-12-07 Forskarpatent I Syd Ab A peptide ligand to impair cancer cell migration
RU2517190C2 (ru) * 2008-08-13 2014-05-27 Внтрисерч Аб Применение производных пептида wnt5-a для лечения меланомы и рака желудка
EP2523974A4 (en) 2010-01-12 2013-11-06 Oncomed Pharm Inc WNT BINDING AGENTS AND USES THEREOF
EP2446895A1 (en) * 2010-10-01 2012-05-02 Stemgen S.P.A. EPH receptor expression in tumor stem cells
US9278119B2 (en) * 2011-07-01 2016-03-08 Wntresearch Ab Treatment of prostate cancer and a method for determining the prognosis for prostate cancer patients
US20140171356A1 (en) 2012-12-12 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Chemically immobilized wnt protein and methods of use
KR102674191B1 (ko) * 2014-12-10 2024-06-11 하이퍼스템 에스에이 뇌암 줄기 세포의 성장, 이동 및 침습성 감소 그리고 뇌종양을 가진 환자의 생존 개선 방법 및 조성물

Also Published As

Publication number Publication date
KR102674191B1 (ko) 2024-06-11
EP3229831B1 (en) 2020-03-11
US10688167B2 (en) 2020-06-23
ES2796973T3 (es) 2020-11-30
EP3229831A1 (en) 2017-10-18
KR20170098861A (ko) 2017-08-30
AU2015359043B2 (en) 2021-09-02
AU2015359043C1 (en) 2022-01-06
NZ732532A (en) 2024-10-25
CA2970140A1 (en) 2016-06-16
AU2015359043A1 (en) 2017-06-29
WO2016092378A1 (en) 2016-06-16
US11357840B2 (en) 2022-06-14
US20200345821A1 (en) 2020-11-05
US20170368158A1 (en) 2017-12-28
DK3229831T3 (da) 2020-06-15
JP2018500390A (ja) 2018-01-11
HK1245152A1 (en) 2018-08-24

Similar Documents

Publication Publication Date Title
JP6921755B2 (ja) 脳腫瘍幹細胞の成長、遊走および浸潤性を低下させ脳腫瘍患者の生存率を改善する方法および組成物
JP7379428B2 (ja) Ｎｋ細胞におけるサイトカイン誘導性ｓｈ２タンパク質の阻害
Lonardo et al. Pancreatic stellate cells form a niche for cancer stem cells and promote their self-renewal and invasiveness
ES2363765T3 (es) Agonistas de fgfr.
CN107709359A (zh) Ror1‑ror2结合的调节剂
Nair Epidermal growth factor receptor family and its role in cancer progression
US10010581B2 (en) Syndecan peptides and polypeptides and uses thereof
Mizejewski Breast Cancer, chemokines, and metastasis: a search for decoy ligands of the CXCR4 receptor
ES2330918T3 (es) Inhibidor del activador del factor de crecimiento de hepatocitos para usar en la modulacion de la angiogenesis y la cardiovascularizacion.
CN105764513A (zh) 干细胞调控ii
US10189881B2 (en) MPS peptides and use thereof
KR20140142733A (ko) Egfl7 표적화 및/또는 결합 폴리펩타이드, 그리고 신생혈관생성을 저해하는 방법
KR102384795B1 (ko) 전이성 암의 치료 및 예방을 위한 제약 조성물 및 방법
TWI609692B (zh) 新穎ｓｔｉｐ１多肽及其用途
US10080777B2 (en) Syndecan peptides and polypeptides and uses thereof
CN111139299B (zh) Josd2蛋白在制备治疗恶性肿瘤药物中的应用
HK1245152B (en) Methods and compositions for reducing growth, migration and invasiveness of brain cancer stem cells and improving survival of patients with brian tumors
Benvenuti et al. Discovery and Function of the HGF/MET and the MSP/RON Kinase Signaling Pathways in Cancer
TWI808063B (zh) 治療或預防癌症的方法
Jiang et al. cGAS-STING signaling in melanoma: regulation and therapeutic targeting
AU2008200559A1 (en) VEGFR-3 Binding peptides and their use for inhibiting angiogenesis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181210

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190830

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20201105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210305

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210305

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20210325

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210604

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210607

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210701

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210728

R150 Certificate of patent or registration of utility model

Ref document number: 6921755

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250